Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 14/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | MC5R | P33032 | 1/20 | 0.71 |
| ▸ | MC3R | P41968 | 1/20 | 0.71 |
| ▸ | MC1R | Q01726 | 1/20 | 0.71 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 2/20 | 0.64 |
| ▸ | HTR7 | P34969 | 2/20 | 0.64 |
| ▸ | HTR6 | P50406 | 2/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22612477 | 0.88 | HTR2A (0.75) | HTR2AKMT2AHTR1AHTR7HTR6 | |
| SCHEMBL948317 | 0.88 | HTR2A (1.00) | HTR2AKMT2A | |
| SCHEMBL23745542 | 0.85 | HTR2A (0.77) | HTR2AKMT2AMC5RMC3RMC1R | |
| SCHEMBL31113939 | 0.84 | KMT2A (1.00) | HTR2AKMT2AMC5RMC3RMC1R | |
| SCHEMBL25169575 | 0.84 | KMT2A (1.00) | HTR2AKMT2AMC5RMC3RMC1R | |
| SCHEMBL798249 | 0.84 | MC1R (1.00) | HTR2AKMT2AMC5RMC3RMC1R | |
| Hydrochloric Acid SCHEMBL23721903 | 0.84 | HTR2A (0.76) | HTR2AKMT2AMC5RMC3RMC1R | |
| SCHEMBL24451304 | 0.83 | HTR2A (1.00) | HTR2AKMT2AHTR1AHTR7HTR6 | |
| SCHEMBL30183412 | 0.83 | HTR2A (1.00) | HTR2AKMT2AHTR1AHTR7HTR6 | |
| SCHEMBL798104 | 0.83 | MTNR1A (0.72) | KMT2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616439-B1 | TRYPTAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN GASTROPATHY | COUNCIL SCIENT IND RES (IN) | 2015-12-16 | — | — | EP | disclosed |
| US-8901317-B2 | Tryptamine derivatives, their preparation and their use in gastropathy | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-12-02 | — | — | US | disclosed |
| US-20130197052-A1 | TRYPTAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN GASTROPATHY | UNIVERSITY OF CALCUTTA (IN) | 2013-08-01 | — | — | US | disclosed |
| EP-2616439-A1 | TRYPTAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN GASTROPATHY | Council of Scientific & Industrial Research (IN) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035406-A1 | TRYPTAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN GASTROPATHY | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197052-A1 | TRYPTAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN GASTROPATHY | HTRA2, AIFM1, SI | HTR2A 88/4885KMT2A 3725/4885MC5R 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.